Skip to main content

Table 1 Baseline characteristics of CHC patients

From: Changes in hepatic fibrosis and vitamin D levels after viral hepatitis C eradication using direct-acting antiviral therapy

Characteristics Total population (n = 80)
Age (years) 57.7 ± 10.5
Sex: male, n (%) 42 (52.5)
Body mass index (kg/m2) 24.4 ± 3.5
Naïve cases, n (%) 42 (52.5)
Cirrhosis, n (%) 63 (78.8)
 Child–Pugh class A 58 (72.5)
 Child–Pugh class B 5 (6.3)
Liver stiffness (kPa)a 19.2 ± 15.3
HCV viral load (log IU/mL) 6.1 ± 0.7
Genotype, n (%)  
 1 44 (55.0)
 3 30 (37.5)
 6 6 (7.5)
Alanine aminotransferase level (U/L) 80.0 ± 53.3
Treatment regimen, n (%)b  
 SOF/DAC 22 (27.5)
 SOF/LED 8 (10.0)
 SOF/VEL 1 (1.25)
 SOF/DAC/RBV 42 (52.5)
 SOF/LED/RBV 6 (7.5)
 SOF/VEL/RBV 1 (1.25)
Sustained virological response, n (%) 80 (100)
  1. an = 49
  2. bDAC, daclatasvir; LED, ledipasvir; RBV, ribavirin; SOF, sofosbuvir; VEL, velpatasvir